Prevalence and trends of suspected cannabinoid hyperemesis syndrome over an 11-year period in Northern California: An electronic health record study.

Autor: Costales B; Division of Research, Kaiser Permanente Northern California, 4480 Hacienda Dr, Pleasanton, CA 94588, USA. Electronic address: brianna.m.costales@kp.org., Lu Y; Division of Research, Kaiser Permanente Northern California, 4480 Hacienda Dr, Pleasanton, CA 94588, USA. Electronic address: wendy.y.lu@kp.org., Young-Wolff KC; Division of Research, Kaiser Permanente Northern California, 4480 Hacienda Dr, Pleasanton, CA 94588, USA. Electronic address: kelly.c.young-wolff@kp.org., Cotton DM; The Permanente Medical Group, 1950 Franklin St., Oakland, CA 94612, USA. Electronic address: dale.m.cotton@kp.org., Campbell CI; Division of Research, Kaiser Permanente Northern California, 4480 Hacienda Dr, Pleasanton, CA 94588, USA. Electronic address: cynthia.i.campbell@kp.org., Iturralde E; Division of Research, Kaiser Permanente Northern California, 4480 Hacienda Dr, Pleasanton, CA 94588, USA. Electronic address: estibaliz.m.iturralde@kp.org., Sterling SA; Division of Research, Kaiser Permanente Northern California, 4480 Hacienda Dr, Pleasanton, CA 94588, USA. Electronic address: stacy.a.sterling@kp.org.
Jazyk: angličtina
Zdroj: Drug and alcohol dependence [Drug Alcohol Depend] 2024 Oct 01; Vol. 263, pp. 112418. Date of Electronic Publication: 2024 Aug 17.
DOI: 10.1016/j.drugalcdep.2024.112418
Abstrakt: Background: As access to cannabis has increased, there has been a rise in a condition called cannabinoid hyperemesis syndrome (CHS). This study estimates annual prevalence of suspected CHS at emergency department visits (ED) over an 11-year period in Northern California.
Methods: This retrospective observational cohort study used electronic health records from Kaiser Permanente Northern California. Two CHS case definitions were used to construct two cohorts of adults (18+) with ≥1 CHS visits from 2009 to 2019. The primary definition used a narrow definition based on past studies (CHS group 1) and an exploratory definition allowed for a broader range of codes (CHS group 2); both definitions required a primary diagnosis of vomiting. Annual prevalence of CHS and annual rates of counts of CHS visits estimated using a log-link Poisson model are reported per group.
Findings: There were 57,227 patients with ≥1 CHS visits included in CHS group 1 and 65,645 patients included in CHS group 2. Over eleven years, CHS increased across groups with the fastest rise in CHS group 1 (prevalence ratio = 2.75, 95 % confidence interval [CI] 2.65-2.85, p<.0001 from 2009 to 2019 vs. prevalence ratio = 2.34, 95 % CI 2.27-2.43). CHS group 1 also exhibited the largest increase in ED visits (rate ratio = 2.35, 95 % CI 2.27-2.43, p<.0001).
Conclusion: In a large California population, suspected CHS increased over time across definitions. Annual prevalence increased by 134-175 %, depending on CHS definition. CHS group 2's definition may have been too broad and changes in ICD-10-CM coding may have impacted estimates.
Competing Interests: Declaration of Competing Interest No conflict declared
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: